---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000037"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-07-06T18:53:55+00:00"
generated_at: "2026-07-06T18:55:06.127697+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# AbCellera appoints Dr. Lynn Seely to Board of Directors as independent Class III director

## Summary
- Dr. Lynn Seely appointed as Class III director effective June 30, 2026, serving until 2029 annual meeting.
- She is independent under Nasdaq rules and will receive standard non-employee director compensation.
- Dr. Seely is President and CEO of Lyell Immunopharma, former CEO of Myovant Sciences, and former CMO of Medivation.
- Her experience includes endocrinology, oncology, and women's health, relevant to AbCellera's antibody-based medicine development.

## SEC filing metadata
- accession: 0001703057-26-000037
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-07-06T18:53:55+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/abcl-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000037
- JSON: https://secwatch.observer/filing/0001703057-26-000037.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000037.txt

## Key facts
- Executive change
  Lynn Seely was appointed as Class III Director at AbCellera Biologics Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.